1. Pharmacokinetics of Mycophenolate Mofetil Metabolites in Older Patients on the Seventh Day After Renal Transplantation
- Author
-
M. Malec, Maria Chrzanowska, M. Głyda, and Joanna Sobiak
- Subjects
medicine.medical_specialty ,Population ,Urology ,Renal function ,Reference range ,Mycophenolic acid ,Glucuronides ,Pharmacokinetics ,medicine ,Humans ,education ,Aged ,Volume of distribution ,Transplantation ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Mycophenolic Acid ,Kidney Transplantation ,Therapeutic drug monitoring ,Area Under Curve ,Surgery ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
Background Currently, immunosuppression schemes are age-independent; however, physiological changes may alter drugs’ pharmacokinetics in the older population. We compared mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) pharmacokinetics among patients aged 60 years on the seventh day after renal transplantation. Methods We included 7 and 10 renal transplant recipients, aged >60 and Results In patients aged >60 years, mean MPA and MPAG concentrations before the next dose and ratio of MPAG area under the concentration-time curve (AUC0-12) to MPA AUC0-12 were higher by 1.6-fold, 1.4-fold, and 1.9-fold, respectively. Other MPAG concentrations appeared to be slightly higher (1.2- to 1.5-fold) in older patients. MPA apparent clearance was similar in both groups, whereas volume of distribution at steady state was slightly higher (1.6-fold) in patients aged >60 years. The variability of most MPA and some MPAG pharmacokinetics was greater in patients aged >60 years. The MPA AUC0-12 target was achieved in 40% and 14% of patients aged 60 years, respectively. The highest MPAG concentrations and AUC0-12 were observed for patients with the lowest glomerular filtration rate. Conclusions Higher variability of MPA and MPAG pharmacokinetic parameters, MPA AUC0-12 above the reference range, higher values of MPAG pharmacokinetics in patients with lower glomerular filtration rates, as well as lower proportion of patients achieving MPA targets all indicate the need for therapeutic drug monitoring in renal transplant recipients aged >60 years and to verify target MPA AUC0-12 for this population.
- Published
- 2021
- Full Text
- View/download PDF